GEORGE YANCOPOULOS - 15 Feb 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Bd. Co-Chair, President & CSO, Director
Signature
/s/**George D. Yancopoulos
Issuer symbol
REGN
Transactions as of
15 Feb 2024
Net transactions value
-$48,863,868
Form type
4
Filing time
20 Feb 2024, 16:03:46 UTC
Previous filing
04 Jan 2024
Next filing
01 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $69,030,474 +172,723 +23% $399.66 925,209 15 Feb 2024 Direct
transaction REGN Common Stock Tax liability $117,894,342 -123,601 -13% $953.83 801,608 15 Feb 2024 Direct
holding REGN Common Stock 5,889 15 Feb 2024 By 401(k) Plan
holding REGN Common Stock 180,000 15 Feb 2024 By Trust for Chldn. F1
holding REGN Common Stock 121,071 15 Feb 2024 by 2022 GRAT I
holding REGN Common Stock 158,410 15 Feb 2024 by 2022 GRAT II

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -172,723 -100% $0.000000* 0 15 Feb 2024 Common Stock 172,723 $399.66 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 As investment trustee of trusts for the benefit of the reporting person's children.
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.